Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACER study of galantamine effects on gait variability and stability in Alzheimer's disease
NL-OMON35628Withdrawn
- Sponsor
- Slotervaartziekenhuis
- Start
- Jan 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of galantamine in Alzheimer's disease (AD) and Dementia, sponsored by Slotervaartziekenhuis. Primary endpoints: Balance assessment with accelerometry, 160-meter walking test and 2 more. Planned start Jan 2012; status: withdrawn.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on NL-OMON35628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35628.